FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
-9.7%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$11.4B
AUM Growth
+$11.4B
(-20%)
Cap. Flow
-$846M
Cap. Flow
% of AUM
-7.42%
Top 10 Holdings %
Top 10 Hldgs %
47.34%
Holding
116
New
12
Increased
50
Reduced
18
Closed
19
Top Buys
| 1 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
$547M |
| 2 |
RHT
Red Hat Inc
RHT
|
$472M |
| 3 |
AABA
Altaba Inc. Common Stock
AABA
|
$369M |
| 4 |
Cigna
CI
|
$200M |
| 5 |
Equinix
EQIX
|
$177M |
Top Sells
| 1 |
AET
Aetna Inc
AET
|
$1.51B |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
$1.13B |
| 3 |
COL
Rockwell Collins
COL
|
$584M |
| 4 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
$257M |
| 5 |
BPYU
Brookfield Property REIT Inc. Class A Common Stock
BPYU
|
$169M |
Sector Composition
| 1 | Communication Services | 28.35% |
| 2 | Healthcare | 24.1% |
| 3 | Technology | 21.57% |
| 4 | Industrials | 8.78% |
| 5 | Consumer Discretionary | 5.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
AstraZeneca
AZN
$248B
| $148M | 1.08% | 3,885,000 +465,000 | +14% | +$17.7M |
|
27
Alibaba
BABA
$322B
| $144M | 1.06% | 1,050,000 +677,000 | +182% | +$92.8M |
|
28
Liberty Global Class A
LBTYA
$4B
| $127M | 0.93% | 5,972,437 -657,165 | -10% | -$14M |
|
|
TSRO
29
DELISTED
TESARO, Inc.
TSRO
| $126M | 0.93% | +1,700,000 | New | +$126M |
|
|
ARRS
30
DELISTED
ARRIS International plc Ordinary Shares
ARRS
| $109M | 0.8% | +3,580,000 | New | +$109M |
|
31
Liberty Global Class C
LBTYK
$4.07B
| $102M | 0.75% | 4,937,202 -2,054,438 | -29% | -$42.4M |
|
32
Ascendis Pharma
ASND
$11.8B
| $93.9M | 0.69% | 1,499,297 +42,000 | +3% | +$2.63M |
|
|
XLRN
33
DELISTED
Acceleron Pharma Inc.
XLRN
| $91.5M | 0.67% | 2,100,000 +259,268 | +14% | +$11.3M |
|
|
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
| $81.9M | 0.6% | 5,750,000 +625,000 | +12% | +$8.91M |
|
|
MYOK
35
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $78.2M | 0.57% | 1,600,278 +69,000 | +5% | +$3.37M |
|
|
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
| $74.8M | 0.55% | 2,050,500 +255,000 | +14% | +$9.3M |
|
|
P
37
DELISTED
Pandora Media Inc
P
| $74.5M | 0.55% | +9,205,000 | New | +$74.5M |
|
38
Sarepta Therapeutics
SRPT
$1.78B
| $69.8M | 0.51% | 640,000 +445,000 | +228% | +$48.6M |
|
39
Enanta Pharmaceuticals
ENTA
$180M
| $65.5M | 0.48% | 925,000 +57,500 | +7% | +$4.07M |
|
40
CVS Health
CVS
$92.8B
| $60.9M | 0.45% | +930,000 | New | +$60.9M |
|
|
GBT
41
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $59.5M | 0.44% | 1,450,000 +80,000 | +6% | +$3.28M |
|
|
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $55.1M | 0.4% | 1,300,000 +425,000 | +49% | +$18M |
|
43
Iovance Biotherapeutics
IOVA
$807M
| $50.7M | 0.37% | 5,725,000 +1,000,000 | +21% | +$8.85M |
|
|
AMRN
44
Amarin Corp
AMRN
$311M
| $47.6M | 0.35% | 3,500,000 +187,300 | +6% | +$2.55M |
|
45
Grifois
GRFS
$6.78B
| $43.7M | 0.32% | 2,381,119 +591,119 | +33% | +$10.9M |
|
46
NovoCure
NVCR
$1.38B
| $41.9M | 0.31% | 1,250,000 -100,000 | -7% | -$3.35M |
|
47
Alnylam Pharmaceuticals
ALNY
$58.5B
| $40.1M | 0.29% | 550,000 +273,449 | +99% | +$19.9M |
|
48
Exelixis
EXEL
$10.1B
| $39.3M | 0.29% | 2,000,000 +920,000 | +85% | +$18.1M |
|
|
RETA
49
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $39.3M | 0.29% | 700,000 +26,500 | +4% | +$1.49M |
|
50
NXP Semiconductors
NXPI
$59.2B
| $39.2M | 0.29% | 535,000 -1,115,000 | -68% | -$81.7M |
|